Get started
Author

Danni Yu

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
2021 · James J. Harding, Victor Moreno, et al. · Clinical Cancer Research · 163
PDF
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
2019 · Ryan J. Sullivan, Antoine Hollebecque, et al. · Molecular Cancer Therapeutics · 92
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
2016 · Muhammad Wasif Saif, James A. Knost, et al. · Cancer Chemotherapy and Pharmacology · 77
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
2020 · Karen A. Autio, Christopher A. Klebanoff, et al. · Clinical Cancer Research · 76
PDF
Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy
2018 · Yu Gao, John C. Kraft, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 60
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials
2024 · Jonathan I. Silverberg, David Rosmarin, et al. · Nature Communications · 55
PDF
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial
2021 · Afshin Dowlati, R. Donald Harvey, et al. · Investigational New Drugs · 55
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
2020 · Amita Patnaik, Timothy A. Yap, et al. · Clinical Cancer Research · 46
PDF
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
2021 · Analia Azaro, Christophe Massard, et al. · Investigational New Drugs · 38
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
2022 · Nizar M Tannir, Daniel C Cho, et al. · Journal for ImmunoTherapy of Cancer · 28
PDF
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
2022 · Arlene O. Siefker-Radtke, Daniel C. Cho, et al. · European Urology · 20
Proteomic analysis of high NaCl-induced changes in abundance of nuclear proteins
2012 · Jinxi Li, Joan D. Ferraris, et al. · Physiological Genomics · 19
Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).
2019 · Karen A. Autio, Christopher Austin Klebanoff, et al. · Journal of Clinical Oncology · 17
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors
2022 · C. Massard, P. A. Cassier, et al. · Cancer Chemotherapy and Pharmacology · 15
A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.
2017 · David S. Hong, Antoine Hollebecque, et al. · Journal of Clinical Oncology · 9
A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.
2017 · Afshin Dowlati, Hope S. Rugo, et al. · Journal of Clinical Oncology · 8
Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study
2026 · Jonathan I Silverberg, David Rosmarin, et al. · The Lancet · 5
ARF1 maintains intestinal homeostasis by modulating gut microbiota and stem cell function
2023 · Danni Yu, Quanhui Dai, et al. · Life Sciences · 5
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
2023 · A. S. Feils, A. K. Erbe, et al. · Cancer Immunology Immunotherapy · 4
PDF
Manipulation of Wnt/β‐Catenin Signaling by Synthetic Frizzled Agonist and LRP Antagonist in Organoid Cultures and In Vivo
2025 · Quanhui Dai, Jiawen Wang, et al. · Small Methods · 3
729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
2024 · Melinda Gooderham, Charles Lynde, et al. · British Journal of Dermatology · 3
205P Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small cell lung cancer
2024 · L. Shi, Z. Liu, et al. · ESMO Open · 3
Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5).
2015 · Wasif M. Saif, James A. Knost, et al. · Journal of Clinical Oncology · 3
65106 Safety profile of Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, versus Placebo Based on Aggregate Safety Evaluation of 746 Subjects Enrolled Across 9 Studies
2025 · Sohail Chaudhry, Melinda Gooderham, et al. · Journal of the American Academy of Dermatology · 2
Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents
2018 · Amita Patnaik, Yung-Jue Bang, et al. · Cancer Research · 2
Works count: 74
Citation count: 809
H-index: 14
I10-index: 14
Year
Topic
Type